FDA Approves Baxalta’s Longer Lasting Therapy for Hemophilia A
November 17, 2015 The US Food and Drug Administration (FDA) recently approved Baxalta’s ADYNOVATE, a new longer- lasting recombinant factor VIII (rFVII) product. The new therapy is indicated for the on-demand treatment of bleeding episodes, and for routine prophylaxis in adult and adolescent patients (12 years and older)